Levi & Korsinsky, LLP Announces Class Action Lawsuit against Trubion Pharmaceuticals, Inc. and Its Board of Directors

Levi & Korsinsky, LLP announces that on October 4, 2010, they filed a class action complaint on behalf of all current stockholders of Trubion Pharmaceuticals, Inc. (“Trubion”) (NASDAQ: TRBN) in connection with Trubion’s attempt to merge with Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS). The complaint charges Trubion and Trubion’s board of directors with, among other things, violations of the Securities Exchange Act of 1934 and Rule 14a-9. In particular, the complaint alleges that the defendants have issued materially false and misleading statements regarding the proposed transaction wherein Trubion intends to merge with Emergent.

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiffs’ counsel, Eduard Korsinsky, at Levi & Korsinsky, LLP, (212) 363-7500 or, or via e-mail at ek@zlk.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.zlk.com. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. AT THIS TIME YOU MAY DO NOTHING AND REMAIN AN ABSENT CLASS MEMBER. YOU MAY ALSO RETAIN COUNSEL OF YOUR CHOICE.

Levi & Korsinsky, LLP is a national law firm that represents the rights of shareholders and victims of corporate abuse. We are headquartered in New York City and have offices in Los Angeles, California and New Jersey. With over 50 years of combined litigation experience, the members of L|K have been involved in hundreds of class action lawsuits and have obtained multi-million dollar recoveries. L|K has been appointed lead counsel or has played a major role on behalf of shareholders in a majority of the merger-related lawsuits that have been filed on behalf of shareholders throughout the country. The firm has therefore developed a specialization of knowledge in shareholder rights and fiduciary duty law.

Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024